Project REVeyeVE - 06/02/2025

Targeted, virus-free gene therapy for the eye using degradable nanopropellers

Eye diseases that result in blindness in young people are primarily caused by genetic mutations. An interdisciplinary team of researchers from the Universities of Tübingen and Heidelberg is developing an innovative gene therapy method using biodegradable, magnetic nanopropellers. These innovative nanopropellers can effectively deliver intact genes into the affected cells, offering a potential solution for treating genetic disorders of this kind.

University of Tübingen research team observes biochemical process in living cells – indications of new approach to preventing heart attacks and strokes

A new family of protein-based antagonists has been created by researchers that efficiently block the granulocyte-colony stimulating factor receptor (G-CSFR), which is essential for the development of leukaemia and other inflammatory illnesses. This groundbreaking work paves the way for targeted therapies that could revolutionise treatment options for patients suffering from these conditions.

The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.

NMI spin-off develops theranostics - 02/12/2024

immuneAdvice develops diagnostics to predict the efficacy of immunotherapies

Certain types of cancer are already being effectively treated using immunotherapies, though success rates can vary significantly between patients. Researchers from the Natural and Medical Sciences Institute (NMI) in Reutlingen, along with colleagues at the University of Tübingen, are working on a diagnostic approach to accompany therapy, which would rapidly assess whether the treatment is effective or requires adjustment.

Cell division, cell differentiation, cell repair and cell death play fundamental roles in the human organism, its development, health and reproduction. Cellular transformation processes are governed by two regulatory mechanisms: chromatin modifications and cell signaling networks. The EpiSignal Research Training Group sheds light on the hitherto little-researched interplay between these two complex systems.

NMI project WOUNDSENS - 23/10/2024

Wound monitoring using sensory nanofibres

Monitoring the condition of chronic, non-healing wounds requires wound dressings to be changed at short, regular intervals. In the EU-funded WOUNDSENS project, researchers at the NMI in Reutlingen are using electrospinning to produce novel types of wound dressings. These consist of biosensory fibres that send information about the condition of the wound to the outside, thereby improving inflammation detection.

Biotechnology team at University of Tübingen obtains valuable byproduct in protein production. This could be a potential to the contribution of feeding a growing world population without livestock farming.

Scientists have long sought ways to simulate the neural networks in the brain with computers in order to understand how it works. Now, researchers have combined new measurements of the wiring diagrams of the fruit fly with artificial intelligence methods to build a neural network that can do what few thought possible: To predict the activity of individual neurons without making a single measurement in a living brain.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

Max Planck scientists will present a low-field magnetic resonance imaging (MRI) scanner in Lindau. Two researchers from the MPI for Biological Cybernetics in Tübingen, Germany, will present a model of a new low-field MRI system. It combines hyperpolarization with imaging techniques that can be run at low magnetic field strengths. The quality of the MRI images can be enhanced with the help of artificial intelligence.

Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.

The Damietta Server broadens the accessibility to protein design research and its applications in various biotechnological and biomedical fields. Researchers at the Max Planck Institute for Biology Tübingen, the University of Tübingen, and the University Hospital Tübingen have developed a web-based toolkit to accelerate and simplify protein design without needing powerful computers or extensive protein design expertise on the user’s end.

Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.

How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.

Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

Pioneering cutting-edge diagnostic systems for the detection of complex diseases: Cyber Valley is pleased to announce it has awarded funding of 500K EUR to the CELL’n’ROLL team through the 2023 Cyber Valley Innovation Fellowship program, funded by the Carl-Zeiss-Stiftung.

Epifadin from the nasal microbiome - 28/03/2024

From the nose: novel antibiotic substance discovered

Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.

Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.

The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.

The German Research Foundation (DFG) has announced the first pivotal decisions for the "Clusters of Excellence" funding line as part of the Excellence Strategy of the German federal and state governments. The University of Stuttgart has been given the green light for two new cluster initiatives.

University of Tübingen neuroscientists discover new functions of head-direction cells suggesting they may contribute to episodic memory formation.

For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.